[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-359914-en":3,"detail-sidebar-cat-0-en-105":50,"doc-seo-359914-105":98},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":11,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"site_id":24,"html_lang":23,"table_of_contents":25,"faqs":26,"seo_title":27,"seo_description":14,"update_tm":28,"read_time":29,"preview_page_count":30,"preview_urls":31},359914,549768702563,"Fahsai","https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083",8,"Research & Report","CCL5hiCD4+ T Cells Regulate Macrophage Polarization and Promote Immunotherapy Response in Bladder Cancer","Immune checkpoint inhibitors (ICI) improve outcomes for subsets of cancer patients, but limited efficacy and treatment resistance demand stronger predictive biomarkers and mechanistic clarity. A distinct population of CCL5hiCD4+ T cells with memory-like activation markers is identified in bladder cancer and correlates with ICI responses. These T cells potentiate antitumor immunity by promoting M1-like macrophage polarization via CCL5/CCR1 signaling. Tumor-derived PGE2 suppresses differentiation of CCR6hiCD4+ T cells into immunostimulatory CCL5hiCD4+ cells, driving ICI resistance. The findings link CD4+ T-cell heterogeneity, myeloid-mediated tumor control, and immune evasion to therapeutic opportunities for enhancing ICI effectiveness.","CCL5hiCD4+ T Cells Regulate Macrophage Polarization and Promote Immunotherapy Response in Bladder Cancer  \nWeiming Luo1, Yapeng Wang1, Haitao Wang1, Ying-ang Ji1, Jian Zhang1, Qiang Ran1, Yangkun Ao1, Jing Xu1, Junying Zhang2, Xiaoyan Cheng3, Luofu Wang1, Yao Zhang1, Jun Zhang1, Can Ai1, Jun Qin1,3,4, Jun Jiang1, Weihua Lan1, and Qiuli Liu1  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Immune checkpoint inhibitors (ICI) have transformed cancer therapy, yet their efficacy remains limited to a subset of patients, underscoring the need for robust predictive biomarkers and deeper mechanistic insights into treatment resistance. In this study, we identified a population of CCL5hiCD4+ T cells that were characterized by memory-like activation markers and strongly correlated with ICI therapeutic responses in bladder cancer. Functionally, these T cells enhanced antitumor immunity by promoting M1-like macrophage polarization through CCL5/ CCR1 signaling. Importantly, tumor-derived prostaglandin E2 (PGE2) acted as a critical microenvironmental factor that suppressed the differentiation of CCR6hiCD4+ T cells into immunostimulatory CCL5hiCD4+ T cells, thereby driving resistance to\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ICI therapy. These findings extend the understanding of CD4+ Tcell heterogeneity and its role in shaping immune responses to ICI. By elucidating that CCL5hiCD4+ T cells enhance myeloidmediated tumor control and that tumor-derived PGE2 disrupts CCL5hiCD4+ T-cell differentiation to promote immune evasion, this work highlights potential therapeutic strategies to improve ICI efficacy in bladder cancer.\u003Cbr>Significance: CCL5hiCD4+ T cells with memory-like activated characteristics enhance antitumor immunity in bladder cancer by reprogramming macrophages, supporting the potential of these cells as biomarkers and targets to enhance immunotherapy efficacy. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nImmune checkpoint inhibitors (ICI) targeting CTLA4 and PD-1/ PD-L1 pathways have transformed cancer treatment by enabling durable tumor regression in subsets of patients (1). Although chemotherapy and radiotherapy remain cornerstones of oncology, ICIsnow constitute first-line therapies for multiple malignancies, including advanced bladder cancer (2). However, clinical responses remain heterogeneous, with nearly 70% of patients with bladder cancer exhibiting suboptimal outcomes due to innate or acquired resistance (3). This stark dichotomy between responders and nonresponders underscores the urgent need to elucidate mechanisms governing ICI efficacy. Deciphering the molecular and immunologic drivers of ICI responsiveness is critical for developing predictive biomarkers and  \n1Department of Urology, Daping Hospital, Army Medical University, Chongqing, People’s Republic of China. 2Chongqing Medical and Pharmaceutical College, Chongqing, People’s Republic of","cbCaicuBWWwLmoun","https://ap.wps.com/l/cbCaicuBWWwLmoun","pdf",11210532,1,16,"English","en",105,"# Introduction\n## Immune checkpoint inhibitors and resistance\n## Need for predictive biomarkers\n## Immune-centric biomarker direction","[{\"question\":\"What is the key discovery about CCL5hiCD4+ T cells in bladder cancer?\",\"answer\":\"CCL5hiCD4+ T cells with memory-like activation markers are identified and strongly correlate with ICI therapeutic responses in bladder cancer.\"},{\"question\":\"How do CCL5hiCD4+ T cells enhance antitumor immunity?\",\"answer\":\"They promote M1-like macrophage polarization through CCL5/CCR1 signaling, strengthening myeloid-mediated tumor control.\"},{\"question\":\"What role does tumor-derived PGE2 play in ICI resistance?\",\"answer\":\"Tumor-derived prostaglandin E2 suppresses differentiation of CCR6hiCD4+ T cells into immunostimulatory CCL5hiCD4+ T cells, promoting resistance to ICI therapy.\"}]","CCL5hiCD4+ T Cells Regulate Macrophage Polarization and Promote Immunotherapy Response in Bladder Cancer | PDF",1790138190,40,4,[32,36,41,46],{"page_no":20,"url":33,"width":34,"height":35},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b9ca643dcb1d591e5d24eae48b5cffb.webp",983,1315,{"page_no":37,"url":38,"width":39,"height":40},2,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/959ccc47f2b4aa96be401f02dba38824.webp",982,1314,{"page_no":42,"url":43,"width":44,"height":45},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d1789013183e56abe8142b31e4926d4.webp",981,1312,{"page_no":30,"url":47,"width":48,"height":49},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0062aa74911704bf9c9818a2839ab7ec.webp",980,1311,{"code":4,"msg":5,"data":51},[52,57,61,65,70,75,79,82,87,90,94],{"id":20,"doc_module":4,"doc_module_name":53,"category_name":54,"show_sort_weight":55,"slug":56},"Document","Story & Novel",90,"story-novel",{"id":37,"doc_module":4,"doc_module_name":53,"category_name":58,"show_sort_weight":59,"slug":60},"Literature",80,"literature",{"id":30,"doc_module":4,"doc_module_name":53,"category_name":62,"show_sort_weight":63,"slug":64},"Exam",70,"exam",{"id":66,"doc_module":4,"doc_module_name":53,"category_name":67,"show_sort_weight":68,"slug":69},5,"Comic",60,"comic",{"id":71,"doc_module":4,"doc_module_name":53,"category_name":72,"show_sort_weight":73,"slug":74},6,"Technology",50,"technology",{"id":76,"doc_module":4,"doc_module_name":53,"category_name":77,"show_sort_weight":29,"slug":78},7,"Healthcare","healthcare",{"id":11,"doc_module":4,"doc_module_name":53,"category_name":12,"show_sort_weight":80,"slug":81},30,"research-report",{"id":83,"doc_module":4,"doc_module_name":53,"category_name":84,"show_sort_weight":85,"slug":86},9,"Religion & Spirituality",20,"religion-spirituality",{"id":85,"doc_module":4,"doc_module_name":53,"category_name":88,"show_sort_weight":85,"slug":89},"World Cup","world-cup",{"id":91,"doc_module":4,"doc_module_name":53,"category_name":92,"show_sort_weight":91,"slug":93},10,"Lifestyle","lifestyle",{"id":95,"doc_module":4,"doc_module_name":53,"category_name":96,"show_sort_weight":66,"slug":97},19,"General","general",{"code":4,"msg":99,"data":100},"ok",{"site_id":24,"language":23,"slug":101,"title":13,"keywords":102,"description":14,"schema_data":103,"social_meta":156,"head_meta":158,"extra_data":160,"updated_unix":161},"ccl5hicd4-t-cells-regulate-macrophage-polarization-and-promote-immunotherapy-response-in-bladder-cancer","",{"@graph":104,"@context":155},[105,118,138],{"@type":106,"itemListElement":107},"BreadcrumbList",[108,112,114,116],{"item":109,"name":110,"@type":111,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":113,"name":53,"@type":111,"position":37},"https://docshare.wps.com/document/",{"item":115,"name":12,"@type":111,"position":42},"https://docshare.wps.com/document/research-report/",{"item":117,"name":13,"@type":111,"position":30},"https://docshare.wps.com/document/ccl5hicd4-t-cells-regulate-macrophage-polarization-and-promote-immunotherapy-response-in-bladder-cancer/359914/",{"url":117,"name":13,"@type":119,"image":120,"author":125,"headline":13,"publisher":127,"fileFormat":130,"inLanguage":23,"description":14,"dateModified":131,"datePublished":132,"encodingFormat":130,"isAccessibleForFree":133,"interactionStatistic":134},"DigitalDocument",{"url":121,"@type":122,"width":123,"height":124},"https://docshare.wps.com/thumbnails/ccl5hicd4-t-cells-regulate-macrophage-polarization-and-promote-immunotherapy-response-in-bladder-cancer/359914.png","ImageObject",300,407,{"name":9,"@type":126},"Person",{"url":109,"name":128,"@type":129},"DocShare","Organization","application/pdf","2026-11-09","2026-09-23",true,{"@type":135,"interactionType":136,"userInteractionCount":11},"InteractionCounter",{"@type":137},"ViewAction",{"@type":139,"mainEntity":140},"FAQPage",[141,147,151],{"name":142,"@type":143,"acceptedAnswer":144},"What is the key discovery about CCL5hiCD4+ T cells in bladder cancer?","Question",{"text":145,"@type":146},"CCL5hiCD4+ T cells with memory-like activation markers are identified and strongly correlate with ICI therapeutic responses in bladder cancer.","Answer",{"name":148,"@type":143,"acceptedAnswer":149},"How do CCL5hiCD4+ T cells enhance antitumor immunity?",{"text":150,"@type":146},"They promote M1-like macrophage polarization through CCL5/CCR1 signaling, strengthening myeloid-mediated tumor control.",{"name":152,"@type":143,"acceptedAnswer":153},"What role does tumor-derived PGE2 play in ICI resistance?",{"text":154,"@type":146},"Tumor-derived prostaglandin E2 suppresses differentiation of CCR6hiCD4+ T cells into immunostimulatory CCL5hiCD4+ T cells, promoting resistance to ICI therapy.","https://schema.org",{"og:url":117,"og:type":157,"og:title":13,"og:site_name":128,"og:description":14},"article",{"robots":159,"canonical":117},"index,follow",{"doc_id":7,"site_id":24},1790663737]